Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – HC Wainwright lowered their FY2024 EPS estimates for shares of Arrowhead Pharmaceuticals in a report issued on Thursday, September 5th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($4.71) for the year, down from their previous forecast of ($3.50). HC Wainwright currently has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2024 earnings at ($1.09) EPS, Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.84) EPS and FY2025 earnings at ($3.56) EPS.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative return on equity of 152.95% and a negative net margin of 163.32%. During the same quarter last year, the firm earned ($0.96) earnings per share. Arrowhead Pharmaceuticals’s revenue for the quarter was down 100.0% on a year-over-year basis.
Get Our Latest Research Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Stock Down 4.4 %
Shares of ARWR stock opened at $22.22 on Monday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -5.23 and a beta of 0.96. Arrowhead Pharmaceuticals has a fifty-two week low of $20.67 and a fifty-two week high of $39.83. The firm’s 50 day moving average price is $25.67 and its two-hundred day moving average price is $26.06.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ARWR. Fifth Third Bancorp raised its holdings in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 354 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 22.9% in the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 447 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Arrowhead Pharmaceuticals by 2.4% in the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 821 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals by 12.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 952 shares during the last quarter. Finally, Securian Asset Management Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 12.5% in the first quarter. Securian Asset Management Inc. now owns 10,100 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 1,121 shares during the last quarter. 62.61% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, insider Tracie Oliver sold 9,394 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the completion of the transaction, the insider now directly owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.50% of the stock is owned by company insiders.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
See Also
- Five stocks we like better than Arrowhead Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.